MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414827 | Name: Pegvaliase

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pegvaliase is a pegylated recombinant Anabaena variabilis-derived phenylalanine ammonia lyase for the treatment of phenylketonuria.

Chemical Structure

Pegvaliase
Pegvaliase
CAS#1585984-95-7

Theoretical Analysis

MedKoo Cat#: 414827

Name: Pegvaliase

CAS#: 1585984-95-7

Chemical Formula: C15H30N2O5

Exact Mass: 318.2155

Molecular Weight: 318.41

Elemental Analysis: C, 56.58; H, 9.50; N, 8.80; O, 25.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Pegvaliase; BMN 165; BMN165; BMN-165; PEG-PAL
IUPAC/Chemical Name
N6-(6-(2-methoxyethoxy)hexanoyl)-L-lysine
InChi Key
NPOCDVAOUKODSQ-ZDUSSCGKSA-N
InChi Code
InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1
SMILES Code
COCCOCCCCCC(NCCCC[C@@H](C(O)=O)N)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 318.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, Harding CO, Bilder DA, Weng HH, Olbertz J, Merilainen M, Jiang J, Larimore K, Gupta S, Gu Z, Northrup H; PRISM investigators. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018 May;124(1):27-38. doi: 10.1016/j.ymgme.2018.03.006. Epub 2018 Mar 31. PMID: 29653686. 2: Mahan KC, Gandhi MA, Anand S. Pegvaliase: a novel treatment option for adults with phenylketonuria. Curr Med Res Opin. 2019 Apr;35(4):647-651. doi: 10.1080/03007995.2018.1528215. Epub 2018 Oct 25. PMID: 30247930. 3: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Pegvaliase. 2021 Aug 16. PMID: 30000994. 4: Markham A. Pegvaliase: First Global Approval. BioDrugs. 2018 Aug;32(4):391-395. doi: 10.1007/s40259-018-0292-3. PMID: 30022433. 5: Hausmann O, Daha M, Longo N, Knol E, Müller I, Northrup H, Brockow K. Pegvaliase: Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy. Mol Genet Metab. 2019 Sep- Oct;128(1-2):84-91. doi: 10.1016/j.ymgme.2019.05.006. Epub 2019 Jun 17. PMID: 31375398. 6: Hydery T, Coppenrath VA. A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria. Drug Target Insights. 2019 Jun 21;13:1177392819857089. doi: 10.1177/1177392819857089. PMID: 31258325; PMCID: PMC6589953. 7: Patrawala M, Kuruvilla M, Li H. Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria. Mol Genet Metab Rep. 2020 Mar 6;23:100575. doi: 10.1016/j.ymgmr.2020.100575. PMID: 32181140; PMCID: PMC7063228. 8: Burton BK, Longo N, Vockley J, Grange DK, Harding CO, Decker C, Li M, Lau K, Rosen O, Larimore K, Thomas J; PAL-002 and PAL-004 Investigators. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. Mol Genet Metab. 2020 Aug;130(4):239-246. doi: 10.1016/j.ymgme.2020.06.006. Epub 2020 Jun 16. PMID: 32593547. 9: Harding CO, Amato RS, Stuy M, Longo N, Burton BK, Posner J, Weng HH, Merilainen M, Gu Z, Jiang J, Vockley J; PRISM-2 Investigators. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Mol Genet Metab. 2018 May;124(1):20-26. doi: 10.1016/j.ymgme.2018.03.003. Epub 2018 Mar 18. PMID: 29628378. 10: Sacharow S, Papaleo C, Almeida K, Goodlett B, Kritzer A, Levy H, Martell L, Wessel A, Viau K. First 1.5 years of pegvaliase clinic: Experiences and outcomes. Mol Genet Metab Rep. 2020 May 25;24:100603. doi: 10.1016/j.ymgmr.2020.100603. PMID: 32489881; PMCID: PMC7256053.